Yale School Of Medicine

MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period

Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of Medicine’s Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100.

Yale Establishes Cannabis Research Center To Study Marijuana's Effect On Neurodevelopment & Mental Health

One of the world's leading centers for biomedical research, advanced clinical care, and medical education, Yale School of Medicine will create a research center to study the acute and chronic effects of cannabis and cannabinoids on neurodevelopment and mental health.